The development, validity, and reliability of the Researcher Investment Tool
Abstract Background: Over the last two decades, there have been significant investments designed to advance clinical and translational research (CTR) with an emphasis on supporting early career investigators and building a cadre of skilled researchers. Despite the investments, there are no compreh...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Cambridge University Press
2025-01-01
|
| Series: | Journal of Clinical and Translational Science |
| Subjects: | |
| Online Access: | https://www.cambridge.org/core/product/identifier/S2059866124006733/type/journal_article |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Abstract
Background:
Over the last two decades, there have been significant investments designed to advance clinical and translational research (CTR) with an emphasis on supporting early career investigators and building a cadre of skilled researchers. Despite the investments, there are no comprehensive measurement tools to track individual-level progress along the research continuum as supports are put in place.
Objective:
The Researcher Investment Tool (RIT) is a novel tool that was created to provide a consistent approach for measuring individual-level changes in the research career trajectory of investigators receiving support from CTR programs.
Methods:
The RIT is a 90-item questionnaire, with eight domains and four sub-domains, designed to measure a researcher’s experiences and perceptions. Several rounds of testing were conducted to assess the tool’s face and content validity as well as the internal consistency and test-retest reliability.
Results:
Psychometric testing revealed strong content validity and good internal consistency with Cronbach’s alpha coefficients ranging from 0.85 to 0.97 across all domains. Test-retest reliability results also revealed stability in the domain measures over time with Pearson’s correlation coefficients ranging from 0.70 to 0.98 for all but one domain (.53).
Conclusions:
This novel RIT may be useful to evaluators when measuring the impact of investments designed to support early career clinical and translational researchers.
|
|---|---|
| ISSN: | 2059-8661 |